Viracta Therapeutics Announces New Employment Inducement Grants
![GlobeNewswire](../../../Content/images/providers/GN.png)
Viracta Therapeutics, Inc. (VIRX)
Company Research
Source: GlobeNewswire
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta’s new Chief Financial Officer, Viracta’s Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each option vests over four years, with 25% of the shares subject to each option vesting on May 13, 2025, and the remaining 75% of the shares subject to each option vesting in equal monthly increments over the succeeding 36 months, in each case subject to the respective grantee’s continuous service to Virac
Show less
Read more
Impact Snapshot
Event Time:
VIRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIRX alerts
High impacting Viracta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VIRX
News
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $13.00 to $11.00. They now have an "outperform" rating on the stock.MarketBeat
- Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerGlobeNewswire